Search Result

Isoforms Recommended:	CBP/p300

Results for "

P300

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Androgen Receptor (2) Apoptosis (12) Autophagy (5) Bacterial (2) Caspase (1) Cholinesterase (ChE) (1) E3 Ligase Ligand-Linker Conjugates (2) Endogenous Metabolite (1) Epigenetic Reader Domain (48) Ferroptosis (3) HIF/HIF Prolyl-Hydroxylase (3) Histone Acetyltransferase (74) Histone Demethylase (1) Influenza Virus (3) Keap1-Nrf2 (3) Ligands for Target Protein for PROTAC (6) MDM-2/p53 (2) Mitophagy (3) Molecular Glues (1) PARP (1) PROTACs (14) Small Interfering RNA (siRNA) (3) STAT (1) Toll-like Receptor (TLR) (2) Wnt (2) β-catenin (2)
By Research Areas:	Cancer (103) Cardiovascular Disease (1) Infection (1) Inflammation/Immunology (7) Metabolic Disease (2) Neurological Disease (5)
Oligonucleotides:	Pre-designed siRNA Sets (3) siRNAs (3)

113

Inhibitors & Agonists

Peptides

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-132197

*CBP/p300-IN-12*	Epigenetic Reader Domain Histone Acetyltransferase	Cancer
CBP/p300-IN-12 is a potent and selective covalent histone acetyltransferases p300 (IC₅₀ of 166 nM) and CBP inhibitor. CBP/p300-IN-12 decreases the levels of H3K27Ac of PC-3 cells (EC₅₀ of 37 nM). CBP/p300-IN-12 forms a covalent adduct with C1450 .

HY-151812

*CBP/p300-IN-20*	Histone Acetyltransferase Epigenetic Reader Domain	Cancer
CBP/p300-IN-20 is a potent and selective *p300/CBP* inhibitor, with a pIC₅₀ of 10.1 for p300. CBP/p300-IN-20 can be used for the research of cancer .

HY-128876

*CBP/p300-IN-3*	Histone Acetyltransferase	Cancer
CBP/p300-IN-3, a p300/CBP histone acetyltransferase inhibitor, Compound 6, is sourced from patent WO 2019049061 A1 .

HY-146445

P300 bromodomain-IN-1	Epigenetic Reader Domain Histone Acetyltransferase	Cancer
P300 bromodomain-IN-1 (Compoun 1u) is a potent p300 (EP300) bromodomain inhibitor with an IC₅₀ of 49 nM. P300 bromodomain-IN-1 suppresses the expression of c-Myc and induces G1/G0 phase arrest and apoptosis in OPM-2 cells .

HY-134621

P300-IN-1	Histone Acetyltransferase	Cancer
P300-IN-1 (cpd205) is a Histone acetylase p300 inhibitor .

HY-121089

P300-IN-5	Others	Others
P300-IN-5 is a biological inhibitor that demonstrates potent activity against histone acetyltransferases (HAT) both in vitro and in vivo. P300-IN-5 may serve as an alternative therapeutic agent, especially in contexts requiring caution, such as during breastfeeding.

HY-139861

*CBP/p300-IN-14*	Epigenetic Reader Domain Histone Acetyltransferase	Cancer
CBP/p300-IN-14 is a potent inhibitor of *CBP/EP300* (lysine acetyltransferase) with an IC₅₀ of 3.3 nM (extracted from patent WO2021213521A1, compound 27) .

HY-146277

*CBP/p300-IN-19*	Histone Acetyltransferase	Cancer
CBP/p300-IN-19 is a potent p300/CBP HAT inhibitor with IC₅₀s of 1.4, 2.2, >100, >100 µM for p300-HAT, CBP-HAT, PCAF, Myst3, respectively. CBP/p300-IN-19 shows antitumor activity .

HY-146277A

*CBP/p300-IN-19 hydrochloride*	Histone Acetyltransferase	Cancer
CBP/p300-IN-19 hydrochloride is a potent and selective p300/CBP HAT inhibitor with IC₅₀s of 1.4, 2.2, >100, >100 µM for p300-HAT, CBP-HAT, PCAF, Myst3, respectively. CBP/p300-IN-19 hydrochloride shows antitumor activity .

HY-155229

*CBP/p300-IN-21*	Epigenetic Reader Domain Histone Acetyltransferase	Cancer
CBP/p300-IN-21 (Compound 5d) is a selective *CBP/p300* inhibitor (IC₅₀: 0.07 and 1.755 μM for p300 and CBP). CBP/p300-IN-21 decreases H3K18Ac level. CBP/p300-IN-21 inhibits growth of 4T1 tumor growth in mice .

HY-161483

*CBP/p300* ligand 3**	Epigenetic Reader Domain Histone Acetyltransferase	Neurological Disease Cancer
CBP/p300 ligand 3 is a target protein ligand of CBPD-268 (HY-161369). CBP and *p300* are two proteins with histone acetyltransferase (HAT) activity, and CBP and *p300* play key roles in regulating biological processes such as gene expression, cell proliferation, differentiation and DNA repair. Through its acetyltransferase activity, *CBP/p300* can acetylate histones and other proteins, thereby regulating chromatin structure and gene expression. CBP/p300 ligand 3 regulates the function of *CBP/p300* by binding to a specific domain of the *CBP/p300* protein (the bromine domain or HAT domain), inhibiting its enzyme activity or altering its interactions with other proteins (transcription factors). CBP/p300 ligand 3 can be used in cancer, neurodegenerative diseases and other disease models associated with abnormal *CBP/p300* function .

HY-161495

*CBP/p300* ligand 4**	Ligands for Target Protein for PROTAC Epigenetic Reader Domain	Cancer
CBP/p300 ligand 4 (Compound 4) is an orally active inhibitor for CBP/p300 bromodomain, with IC₅₀ of 91.4 nM. CBP/p300 ligand 4 serves as a ligand for target protein XYD190 (HY-161495). XYD190 is a PROTAC degrader for CBP/p300 .

HY-138536

*PROTAC CBP/P300* Degrader-1** 1 Publications Verification	PROTACs Epigenetic Reader Domain	Cancer
PROTAC CBP/P300 Degrader-1 is a potent PROTAC CBP/P300 degrader. PROTAC CBP/P300 Degrader-1 potently inhibited cell viability of multiple cancer cell lines .

HY-100132

*CBP/p300-IN-5*	Histone Acetyltransferase	Cancer
P300/CBP-IN-5 is a potent p300/CBP histone acetyltransferase inhibitor extracted from patent WO2016044770A1, Example 715, has an IC₅₀ of 18.8 nM .

HY-143339

*CBP/p300-IN-15*	Epigenetic Reader Domain Histone Acetyltransferase	Cancer
CBP/p300-IN-15 (compound 13a) is a potent *p300/CBP* inhibitor, with IC₅₀ values of 2.50 and 28.0 nM, respectively. CBP/p300-IN-15 shows good activity against OVCAR-3 and A2780 cell line, with EC₅₀ values of 0.865 and 2.71 μM, respectively. CBP/p300-IN-15 can be used for ovarian cancer research .

HY-128875

*CBP/p300-IN-10*	Histone Acetyltransferase	Cancer
CBP/p300-IN-10 is a highly potent histone acetyltransferase EP300 and CREBBP with IC₅₀ values of 26 nM and 39 nM, respectively. CBP/p300-IN-10 can be used to research anticancer .

HY-136920

*CBP/p300-IN-8* 1 Publications Verification	Epigenetic Reader Domain	Cancer
CBP/p300-IN-8 is a potent inhibitor of the CBP/P300 family of bromodomains. CBP/p300-IN-8 inhibits CBP (IC₅₀=0.01-0.1 µΜ) and BRD4 (IC₅₀=1-1000 µΜ) activity .

HY-111420

*CBP/p300-IN-1*	Epigenetic Reader Domain	Cancer
CBP/p300-IN-1 is a *CBP/EP300* bromodomain inhibitor.

HY-138539

*CBP/p300* ligand 2**	Ligands for Target Protein for PROTAC	Cancer
CBP/p300 ligand 2 is a ligand for target protein for PROTAC of dCBP-1. dCBP-1 is a potent and selective heterobifunctional degrader of p300/CBP .

HY-161711

*CBP/p300* ligand 5**	Ligands for Target Protein for PROTAC	Cancer
CBP/p300 ligand 5 is the target protein ligand of XYD129 (HY-161710). CBP/p300 ligand 5 can be used to study the acute myelogenous leukemia .

HY-139707

*Thalidomide-NH-CBP/p300* ligand 2**	PROTACs Molecular Glues Epigenetic Reader Domain	Cancer
Thalidomide-NH-CBP/p300 ligand 2 (P-007) is a PROTAC-based CBP and p300 degrader (extracted from patent WO2020173440) .

HY-139108

DCH36_06	Histone Acetyltransferase Apoptosis	Cancer
DCH36_06 is a potent and selective *p300/CBP* inhibitor with IC₅₀s of 0.6 μM and 3.2 μM for *p300* and CBP, respectively. DCH36_06 mediated p300/CBP inhibition leading to hypoacetylation on H3K18 in leukemic cells. Anti-tumor activity .

HY-143441

*CBP/p300-IN-17*	Histone Acetyltransferase	Cancer
CBP/p300-IN-17 (compound 7) is a potent EP300/CBP HAT inhibitor with IC₅₀s of 0.18, 0.69 µM for HAT EP300 and LK2 H3K27, respectively .

HY-143442

*CBP/p300-IN-18*	Histone Acetyltransferase	Cancer
CBP/p300-IN-18 (compound 8) is a potent EP300/CBP HAT inhibitor with IC₅₀s of 0.056, 0.46 µM for HAT EP300 and LK2 H3K27, respectively .

HY-143440

*CBP/p300-IN-16*	Histone Acetyltransferase	Cancer
CBP/p300-IN-16 (compound 1) is a potent EP300/CBP HAT inhibitor with IC₅₀s of 0.61, 2.24 µM for HAT EP300 and LK2 H3K27, respectively .

HY-136938

NEO2734 1 Publications Verification EP31670	Epigenetic Reader Domain Histone Acetyltransferase	Cancer
NEO2734 (EP31670) is an orally active dual *p300/CBP* and BET bromodomain selective inhibitor, with IC₅₀ values of <30 nM for both p300/CBP and BET bromodomains . NEO2734 is active in SPOP mutant and wild-type prostate cancer .

HY-131035

Lys-CoA TFA	Histone Acetyltransferase	Cancer
Lys-CoA TFA is a selective *p300* histone acetyltransferase (HAT) inhibitor (IC₅₀=50-500 nM). Lys-CoA TFA displays >100-fold selectivity for p300 over PCAF (IC₅₀=200 μM). Lys-CoA TFA inhibits p300 HAT activity-dependent transcriptional activation .

HY-147261

B026	Histone Acetyltransferase	Cancer
B026 is a selective, potent, orally active p300/CBP histone acetyltransferase (HAT) inhibitor with IC₅₀ values of 1.8 nM and 9.5 nM for p300 and CBP enzyme, respectively. B026 has anticancer activity for androgen receptor-positive (AR+) prostate cancer cell lines .

HY-115539

Windorphen	Wnt β-catenin Histone Acetyltransferase	Cancer
Windorphen is a Wnt/β-catenin signal inhibitor that specifically targets the function of the c-terminal transactivation domain of β-catenin-1 but not β-catenin-2. Windorphen selectively targets *p300, disrupting the association of the mammalian β-catenin with p300* but not CBP .

HY-139804

CTK7A	Epigenetic Reader Domain Histone Acetyltransferase HIF/HIF Prolyl-Hydroxylase	Cancer
CTK7A is a curcumin derivative with anticancer activity by inhibiting the HAT activity of *p300* and reducing the autoacetylation of *p300, thereby affecting its interaction with HIF-1α. The inhibition of CTK7A leads to decreased HIF-1α* accumulation and activity, which can be used for cancer treatment research .

HY-162259

QC-182	PROTACs Histone Acetyltransferase	Cancer
QC-182 is a potent PROTAC degrader of *p300/CBP. QC-182 reduces p300* protein in the SK-HEP-1 cells (DC₅₀ = 93nM). QC-182 potently and effectively inhibits cell growth in the SK-HEP-1 and JHH7 cell lines with IC₅₀ values of 0.733 and 0.477 μM, respectively. QC-182 can be used for the research of hepatocellular carcinoma (HCC) .

HY-161710

XYD129	PROTACs Epigenetic Reader Domain Histone Acetyltransferase	Cancer
XYD129 is an effective CBP/p300 PROTAC degrader. XYD129 has antiproliferative activity on MV4-11 cell line (IC ₅₀=0.044 μM). XYD129 can be used for the study of acute myeloid leukemia (AML). (Srtucture Note: Pink, *CBP/p300* ligand 5 (HY-161711); Blue, E3 ligase ligand (HY-41547); Black, Linker (HY-40178)) .

HY-134591

Thalidomide-NH-PEG4-COOH	E3 Ligase Ligand-Linker Conjugates Autophagy Apoptosis	Cancer
Thalidomide-NH-PEG4-COOH is an E3 ligase ligand-linker conjugate which can be used for synthesizing dCBP-1. dCBP-1 is a potent and selective heterobifunctional degrader of p300/CBP .

HY-134592

Piperidine-GNE-049-N-Boc	Ligands for Target Protein for PROTAC	Cancer
Piperidine-GNE-049-N-Boc is a ligand for target protein for PROTAC of dCBP-1 (HY-134582). dCBP-1 is a potent and selective heterobifunctional degrader of p300/CBP .

HY-123009

KCN1	HIF/HIF Prolyl-Hydroxylase Histone Acetyltransferase	Cancer
KCN1 is a *p300/HIF-1α* interaction inhibitor. KCN1 inhibits HIF transcriptional activity by binding to the CH1 domain of p300 and preventing the p300/HIF-1α assembly. KCN1 exerts antitumor activities through cell cycle arrest .

HY-134582

dCBP-1 3 Publications Verification	PROTACs Epigenetic Reader Domain	Cancer
dCBP-1 is a potent and selective heterobifunctional degrader of *p300/CBP* based on Cereblon ligand. dCBP-1 is exceptionally potent at killing multiple myeloma cells and ablates oncogenic enhancer activity driving MYC expression .

HY-107455

A-485 50+ Cited Publications	Epigenetic Reader Domain Histone Acetyltransferase	Cancer
A-485 is a potent and selective catalytic inhibitor of *p300/CBP* with IC₅₀s of 9.8 nM and 2.6 nM for *p300* and CBP histone acetyltransferase (HAT), respectively .

HY-168201

MJP6412	PROTACs Histone Acetyltransferase	Cancer
MJP6412 is a potent degrader *p300/CBP, with DC₅₀* of 1.6 and 1.2 nM for p300 and CBP, respectively. MJP6412 plays an important role in cancer research .

HY-128761

*CBP/p300-IN-2*	Epigenetic Reader Domain	Cancer
CBP/EP300-IN-2 is an inhibitor of *CBP/EP300* with IC₅₀ values of 1.07 nM and 5.96 nM for CBP/HTRF and Myc, respectively. CBP/EP300-IN-2, example 25, is extracted from patent WO2017205538A1 .

HY-19541

I-CBP112 3 Publications Verification	Histone Acetyltransferase Epigenetic Reader Domain	Cancer
I-CBP112 is a specific and potent acetyl-lysine competitive protein-protein interaction inhibitor, that inhibits the *CBP/p300* bromodomains, enhances acetylation by p300.

HY-120290

PU141	Histone Acetyltransferase	Cancer
PU141 is a selected pyridoisothiazolone HAT inhibitor. PU141 is selective toward CBP and *p300*. PU141 induces cellular histone hypoacetylation and inhibits growth of several neoplastic cell lines originating from different tissues. Anticancer activity .

HY-161494

XYD190	PROTACs Epigenetic Reader Domain	Cancer
XYD190 (Compound 14g) is an orally active degrader for CBP/p300. XYD190 inhibits CBP/p300 bromodomain with IC₅₀ of 483.7 nM. XYD190 exhibits antitumor activity against acute myeloid leukemia. (Structure: Pink, CBP/p300 ligand 4 (HY-161495); Blue, E3 ligase ligand (HY-14658); Black: linker (HY-161496)) .

HY-161498

XYD198	PROTACs Epigenetic Reader Domain	Cancer
XYD198 (Compound 14h) is an orally active degrader for CBP/p300. XYD198 inhibits CBP/p300 bromodomain with IC₅₀ of 213.5 nM. XYD198 exhibits antitumor activity against acute myeloid leukemia. (Structure: Pink, CBP/p300 ligand 4 (HY-161495); Blue, E3 ligase ligand (HY-14658); Black: linker (HY-161499))

HY-162128

Antitumor agent-130	Histone Acetyltransferase	Cancer
Antitumor agent-130 (Compound 7b) is a *p300* histone acetyltransferases (HAT) inhibitor with an IC₅₀ of 1.51 μM. Antitumor agent-130 combinates with doxorubicin (HY-15142A) can significantly inhibit tumor growth and invasion in vitro and in vivo .

HY-124960

CTPB 3 Publications Verification	Histone Acetyltransferase	Cancer
CTPB is a good activator of p300 histone acetyl transferase (HAT) enzyme .

HY-139148

UMB298	Epigenetic Reader Domain	Cancer
UMB298 is a potent and selective *CBP/P300* bromodomain inhibitor .

HY-168148S

CZL-046	Epigenetic Reader Domain	Cancer
CZL-046 (compund 29) is an oral *p300* bromodomain inhibitor .

HY-N0005S

Curcumin-d6 Diferuloylmethane-d₆; Natural Yellow 3-d₆; Turmeric yellow-d₆	Keap1-Nrf2 Ferroptosis Autophagy Histone Acetyltransferase Epigenetic Reader Domain Mitophagy Influenza Virus	Infection Metabolic Disease Inflammation/Immunology
Curcumin-d₆is a deuterium labeled Curcumin (Turmeric yellow). Curcumin (Turmeric yellow) is a natural phenolic compound with diverse pharmacologic effects including anti-inflammatory, antioxidant, antiproliferative and antiangiogenic activities. Curcumin is an inhibitor of p300 histone acetylatransferase (HATs) and also shows inhibitory effects on NF-κB and MAPKs.

HY-124696

PU139 3 Publications Verification	Histone Acetyltransferase	Cancer
PU139 is a potent pan-histone acetyltransferase (HAT) inhibitor. PU139 blocks the HATs Gcn5, p300/CBP-associated factor (PCAF), CREB (cAMP response element-binding) protein (CBP) and p300 with IC₅₀s of 8.39, 9.74, 2.49 and 5.35 μM, respectively .

HY-161369

CBPD-268	PROTACs Histone Acetyltransferase	Cancer
CBPD-268 is a potent and orally active *CBP/p300* PROTAC degrader with an DC₅₀ value of ≤ 0.03 nM. CBPD-268 induces CBP/p300 degradation and inhibits cell growth. CBPD-268 shows antitumor activity. CBPD-268 has the potential for the research of AR-positive prostate cancer (Srtucture Note: Red, Androgen receptor degrader (HY-W248665A); Blue, CBP/p300 ligand (HY-161483); Black, Linker) .

Cat. No.	Product Name	Target	Research Area

HY-P10238

MYBMIM	Apoptosis	Cancer
MYBMIM is an inhibitor for assembly of the molecular *MYB:CBP/P300* complex. MYBMIM inhibits growth of leukemia cells .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N2020

Anacardic Acid 5+ Cited Publications Hydroginkgolic acid; Ginkgolic Acid C15:0	Structural Classification Ginkgoaceae Classification of Application Fields Source classification Plants Ginkgo biloba Monophenols Ketones, Aldehydes, Acids Phenols Anacardium occidentaleL. Disease Research Fields Anacardiaceae Cancer	Histone Acetyltransferase Epigenetic Reader Domain Bacterial
Anacardic Acid, extracted from cashew nut shell liquid, is a histone acetyltransferase inhibitor, inhibits HAT activity of p300 and PCAF, with IC₅₀s of ∼8.5 μM and ∼5 μM, respectively.

HY-N0005

Curcumin Maximum Cited Publications 71 Publications Verification Diferuloylmethane; Natural Yellow 3; Turmeric yellow	Structural Classification Classification of Application Fields Anti-aging Source classification Plants Food Research Microorganisms Sunscreen Phenols Polyphenols Pigments Cosmetic Research Curcuma longa Disease Research Fields Zingiberaceae Cancer	Histone Acetyltransferase Epigenetic Reader Domain Keap1-Nrf2 Autophagy Mitophagy Influenza Virus Ferroptosis
Curcumin (Diferuloylmethane), a natural phenolic compound, is a p300/CREB-binding protein-specific inhibitor of acetyltransferase, represses the acetylation of histone/nonhistone proteins and histone acetyltransferase-dependent chromatin transcription. Curcumin shows inhibitory effects on NF-κB and MAPKs, and has diverse pharmacologic effects including anti-inflammatory, antioxidant, antiproliferative and antiangiogenic activities. Curcumin induces stabilization of Nrf2 protein through Keap1 cysteine modification.

HY-107569

Garcinol 1 Publications Verification	Structural Classification Classification of Application Fields Guttiferae Phenols Polyphenols Plants Inflammation/Immunology Disease Research Fields Garcinia indica	Cholinesterase (ChE) Histone Acetyltransferase Apoptosis Endogenous Metabolite
Garcinol, a polyisoprenylated benzophenone harvested from Garcinia indica, exerts anti-cholinesterase properties towards acetyl cholinesterase (AChE) and butyrylcholinesterase (BChE) with IC₅₀s of 0.66 µM and 7.39 µM, respectively . Garcinol also inhibits histone acetyltransferases (HATs, IC₅₀= 7 μM) and p300/CPB-associated factor (PCAF, IC₅₀ = 5 μM). Garcinol has anti-inflammatory and anti-cancer activity .

HY-N2345

Procyanidin B3	Structural Classification Classification of Application Fields Source classification Plants Flavonoids other families Functional Molecules Research of Health Products Phenols Polyphenols Biflavones Disease Research Fields Cancer	Histone Acetyltransferase Toll-like Receptor (TLR) Androgen Receptor
Procyanidin B3 is a natural product with antioxidant activity and oral bioavailability, possessing good blood-brain barrier penetration. Procyanidin B3 is a selective inhibitor of histone acetyltransferase (HAT). By inhibiting p300 HAT-mediated acetylation of the androgen receptor (androgen receptor). Procyanidin B3 alleviates intervertebral disc degeneration (IVDD) by inhibiting the formation of the TLR4/MD-2 complex. Procyanidin B3 can be used in research on prostate cancer and arthritis .

HY-N2020R

Anacardic Acid (Standard)	Structural Classification Monophenols Ginkgoaceae Ketones, Aldehydes, Acids Source classification Phenols Plants Anacardium occidentaleL. Ginkgo biloba Anacardiaceae	Histone Acetyltransferase Epigenetic Reader Domain Bacterial
Anacardic Acid (Standard) is the analytical standard of Anacardic Acid. This product is intended for research and analytical applications. Anacardic Acid, extracted from cashew nut shell liquid, is a histone acetyltransferase inhibitor, inhibits HAT activity of p300 and PCAF, with IC₅₀s of ～8.5 μM and ～5 μM, respectively.

HY-N0005R

Curcumin (Standard)	Structural Classification Microorganisms Source classification Phenols Polyphenols Plants Curcuma longa Zingiberaceae	Histone Acetyltransferase Epigenetic Reader Domain Keap1-Nrf2 Autophagy Mitophagy Influenza Virus Ferroptosis
Curcumin (Standard) is the analytical standard of Curcumin. This product is intended for research and analytical applications. Curcumin (Diferuloylmethane), a natural phenolic compound, is a p300/CREB-binding protein-specific inhibitor of acetyltransferase, represses the acetylation of histone/nonhistone proteins and histone acetyltransferase-dependent chromatin transcription. Curcumin shows inhibitory effects on NF-κB and MAPKs, and has diverse pharmacologic effects including anti-inflammatory, antioxidant, antiproliferative and antiangiogenic activities. Curcumin induces stabilization of Nrf2 protein through Keap1 cysteine modification.

HY-N2345R

Procyanidin B3 (Standard)	Structural Classification Flavonoids other families Source classification Phenols Polyphenols Plants Biflavones	Histone Acetyltransferase Toll-like Receptor (TLR) Androgen Receptor
Procyanidin B3 (Standard) is the analytical standard of Procyanidin B3. This product is intended for research and analytical applications. Procyanidin B3 is a natural product with antioxidant activity and oral bioavailability, possessing good blood-brain barrier penetration. Procyanidin B3 is a selective inhibitor of histone acetyltransferase (HAT). By inhibiting p300 HAT-mediated acetylation of the androgen receptor (androgen receptor). Procyanidin B3 alleviates intervertebral disc degeneration (IVDD) by inhibiting the formation of the TLR4/MD-2 complex. Procyanidin B3 can be used in research on prostate cancer and arthritis .

Species:	Human (2)
Tag:	His (1) GST (1)
Source:	Sf9 insect cells (1) E. coli (1)

Cat. No.	Compare	Product Name	Species	Source

HY-P702963

	EP300 Protein, Human (sf9, GST) P300; P300 HAT; Histone acetyltransferase P300	Human	Sf9 insect cells
	EP300 Protein, Human (sf9, GST) is the recombinant human-derived EP300, expressed by Sf9 insect cells , with GST labeled tag. The total length of EP300 Protein, Human (sf9, GST) is 391 a.a.,

HY-P702892

	EP300 Protein, Human (His) P300	Human	E. coli
	EP300 Protein, Human (His) is the recombinant human-derived EP300, expressed by E. coli , with N-6*His labeled tag. The total length of EP300 Protein, Human (His) is 118 a.a.,

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name	Chemical Structure

HY-N0005S

Curcumin-d6
Curcumin-d₆is a deuterium labeled Curcumin (Turmeric yellow). Curcumin (Turmeric yellow) is a natural phenolic compound with diverse pharmacologic effects including anti-inflammatory, antioxidant, antiproliferative and antiangiogenic activities. Curcumin is an inhibitor of p300 histone acetylatransferase (HATs) and also shows inhibitory effects on NF-κB and MAPKs.

HY-168148S

CZL-046
CZL-046 (compund 29) is an oral *p300* bromodomain inhibitor .

HY-160261S

EP300/CBP-IN-2
EP300/CBP-IN-2 is a potent *EP300/CBP* inhibitor that has good activity in vivo. EP300/CBP-IN-2 can be used for the research of cancer .

Cat. No.	Compare	Product Name	Application	Reactivity

HY-P80775

	p300 Antibody EP300; P300; Histone acetyltransferase P300; P300 HAT; E1A-associated protein P300	ICC/IF, WB, IHC-F, IHC-P, ELISA	Human, Mouse, Rat
	p300 Antibody is a non-conjugated and Rabbit origined polyclonal antibody about 264 kDa, targeting to p300. It can be used for ICC/IF,WB,IHC-F,IHC-P,ELISA assays with tag free, in the background of Human, Mouse, Rat.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

P300

Inhibitors & Agonists

Peptides

NaturalProducts

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Oligonucleotides

Natural
Products